companiesCompany
Telix Pharmaceuticals
Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline.
Illuccix/Gozellix (68Ga-PSMA-11), TLX250-CDx (89Zr-girentuximab, CA9 kidney PET, FDA CRL 2025), TLX591 (177Lu-rosopatamab, PSMA antibody, ProstACT phase 3), TLX101 (glioma).
Pages like this
not linked directly; found by shared links- CompanyLantheus
Shares Radionuclide generators and cold kits, PET tracer manufacturing and distribution, Prostate cancer.
- IdeaBiomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)
- TechnologyRadio-antibody & radio-ADC
Shares CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy, PSMA, Renal cell carcinoma.
- CompanyCurium
Shares Radionuclide generators and cold kits, Prostate cancer.
- TechnologyMedical cyclotrons, hot cells, and synthesis modules
Shares Radionuclide generators and cold kits, PET tracer manufacturing and distribution.
- CompanyClarity Pharmaceuticals
Shares PSMA, Prostate cancer.
- PersonJeremie Calais
Shares PSMA, Prostate cancer.
- ProductFlotufolastat F-18
Shares PSMA, Prostate cancer.